Omeros (OMER) to Release Quarterly Earnings on Monday

Omeros (NASDAQ:OMER) is expected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Omeros Stock Performance

Shares of Omeros stock opened at $7.06 on Friday. The company has a 50-day simple moving average of $8.56 and a two-hundred day simple moving average of $7.63. The stock has a market capitalization of $409.93 million, a PE ratio of -3.06 and a beta of 2.35. Omeros has a 52-week low of $2.97 and a 52-week high of $13.60.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on OMER shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.